VEGFA and retinal ischemia: However, the lack of superiority of combined therapy over anti-VEGF monotherapy in several studies may be attributed to their design, which often included ME cases regardless of perfusion status or severity of retinal ischemia, or employed inconsistent timing of PRP, sometimes exceeding six months post-diagnosis [17–19].